Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome "BEAUTY-II"

Recruiting

Phase 4 Results N/A

Summary of Purpose

The purpose of this study is to evaluate the efficacy and safety of 5mg maintenance dose (MD) of prasugrel in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) with BiomatrixTM stent.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 May 2015.

1 Sep 2014 6 May 2015 1 Aug 2017 1 Aug 2017 1 May 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Myung-Ho Jeong, PhD

    +82-062-220-5114